Biphosphonates, despite accounting for 70.3% of the overall consumption, only reached 53.1% of the overall expenditure on osteoporosis medication, while parathyroid hormones, representing only 2.3% of the overall consumption accounted for 18.3% of osteoporosis pharmaceutical expenditure. This evidence concerns the gene PTH and osteoporosis.